Β-catenin expression in in situ and infiltrative ductal carcinomas of the breast
- PMID: 21935866
- DOI: 10.5146/tjpath.2011.01073
Β-catenin expression in in situ and infiltrative ductal carcinomas of the breast
Abstract
Objective: Cascades that include β-catenin that has a function in adhesion and interaction with tumor suppressor genes such as APC have important roles in many neoplasms. The aim of the current study was to confirm the effect of the β-catenin pathway in breast tumor carcinogenesis and invasion.
Material and method: Polyclonal rabbit β-catenin antibody was applied to 52 cases of infiltrative ductal carcinoma and 28 cases of ductal carcinoma in situ using the Avidin Biotin complex immune peroxidase method. The intensity and cellular localization of immunostaining were evaluated and compared.
Results: β-catenin immunoreactivity similar to that of normal epithelium was observed in 7 (8.75%) cases and weak or absent β-catenin expression was noted in 45 (56.25%) infiltrative ductal carcinoma cases. β-catenin expression was strong in 5 (6.25%) cases of ductal carcinoma in situ but weak or absent immunostaining was observed in 23 (28.75%) cases. Membranous β-catenin immunoreactivity was observed in 18 (22.5%) cases of infiltrative and 14 (%17.5) cases of ductal carcinoma in situ. Cytoplasmic immunostaining or complete absence of staining was noted in 34 (42.5%) cases of infiltrative and 14 (17.5%) cases of ductal carcinoma in situ.
Conclusion: Similar quantitative and qualitative changes in β-catenin expression were detected in a considerable proportion of in situ and infiltrative ductal carcinomas in the current study. These findings suggest that β-catenin plays a role in the carcinogenesis of infiltrative ductal carcinoma but similar expression patterns of β-catenin in infiltrative and in situ ductal carcinomas indicates that changes in β-catenin expression occur early in carcinogenesis.
Similar articles
-
Expression patterns of beta-catenin in in situ and invasive breast cancer.Eur J Surg Oncol. 2001 Feb;27(1):31-6. doi: 10.1053/ejso.1999.1017. Eur J Surg Oncol. 2001. PMID: 11237489
-
Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.Breast Cancer Res. 2008;10(5):R87. doi: 10.1186/bcr2157. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928525 Free PMC article.
-
Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.Chin Med J (Engl). 2007 Sep 20;120(18):1597-605. Chin Med J (Engl). 2007. PMID: 17908479
-
Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.Mod Pathol. 2000 Jan;13(1):37-45. doi: 10.1038/modpathol.3880007. Mod Pathol. 2000. PMID: 10658908
-
Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.APMIS Suppl. 2003;(108):1-67. APMIS Suppl. 2003. PMID: 12874968 Review.
Cited by
-
The Expression of Signaling Genes in Breast Cancer Cells.Biology (Basel). 2022 Apr 3;11(4):555. doi: 10.3390/biology11040555. Biology (Basel). 2022. PMID: 35453754 Free PMC article.
-
Association of Genetic Polymorphisms in CDH1 and CTNNB1 with Breast Cancer Susceptibility and Patients' Prognosis among Chinese Han Women.PLoS One. 2015 Aug 18;10(8):e0135865. doi: 10.1371/journal.pone.0135865. eCollection 2015. PLoS One. 2015. PMID: 26285011 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous